Major Funds See Value in BioNTech’s Depressed Shares

While BioNTech stock trades near its 52-week low, a significant shift is occurring behind the scenes. Prominent institutional investors are interpreting the current valuation as a compelling buying opportunity, with several asset managers making substantial additions to their holdings. This accumulation coincides with renewed optimism from equity researchers regarding the company’s long-term pipeline.

The bullish sentiment is partly fueled by positive analyst commentary. Berenberg recently reaffirmed its buy rating on the stock and increased its price target to $155. This adjustment suggests a potential upside of over 60% from recent trading levels.

The primary driver for this upgraded outlook is progress in BioNTech’s oncology portfolio. Read more...